NASDAQ$BNGO
BioNano Genomics Inc · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
Reported financial results for the fourth quarter and full year ended December 31, 2022.
Bionano Genomics reported a 30% increase in Q4 revenue compared to Q4 2021, reaching $8.2 million. The company's gross margin for the quarter was 22%, a significant increase from 4% in the same period last year. Bionano exceeded its 2022 revenue guidance and saw an increase in the adoption of optical genome mapping (OGM).
- Q4 revenue increased by 30% compared to Q4 2021, reaching $8.2 million.
- Gross margin for Q4 2022 was 22%, compared to 4% in Q4 2021.
- Installed base of Saphyr systems totaled 240 at year-end, a 46% increase over 2021.
- Sold 4,781 flowcells in Q4 2022, a 49% increase over Q4 2021.
Headline financials
Revenue & EPS history
BioNano · Revenue · Quarterly
$8.22M
Revenue by segment
BioNano · $8.22M total across 2 segments · Q4 2022
- Product Revenue$6.18M+60.5%75.2%
- Service and Other Revenue$2.04M-16.9%24.8%
Forward guidance
Bionano expects full year 2023 revenue to be in the range of $35 million to $38 million. The company anticipates the installed base of OGM systems will total 325 by the end of 2023.
Tailwinds
- Full year 2023 revenue expected to be in the range of $35 million to $38 million, representing a 26% to 37% growth over full year 2022 revenue.
- Installed base of OGM systems expected to total 325 by the end of 2023.
- Acquisition of Purigen Biosystems expected to accelerate the adoption of OGM.
- Well-positioned to execute on goal to drive value for stakeholders.
- Impressive year-over-year revenue growth of 30%.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2022
-3.3%
Avg return
Earnings day
-6.2%
Avg return
5 days after
-8.0%
Avg return
30 days after
40%
12 / 30 earnings
Positive
+15.5%
Q4 2018
Best reaction
-29.8%
Q4 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.8% | -9.5% | — | |
| Q4 2025 | +0.9% | -20.5% | -17.1% | |
| Q3 2025 | +2.8% | +4.8% | +10.2% | |
| Q1 2025 | +2.9% | +0.8% | -2.4% | |
| Q4 2024 | +11.1% | +8.6% | +43.4% | |
| Q3 2024 | -3.4% | -11.5% | -7.7% | |
| Q2 2024 | -21.5% | -23.5% | -13.7% | |
| Q1 2024 | +2.7% | +7.3% | -9.4% | |
| Q4 2023 | +0.0% | -5.8% | -18.2% | |
| Q3 2023 | -7.0% | -10.5% | +2.8% | |
| Q2 2023 | -0.2% | -13.9% | -15.7% | |
| Q1 2023 | +6.9% | -9.6% | +0.0% | |
| Q4 2022 | -8.4% | -5.3% | -19.8% | |
| Q3 2022 | +2.7% | +2.2% | -6.3% | |
| Q2 2022 | +6.6% | +0.0% | +2.2% | |
| Q1 2022 | -16.1% | -24.2% | -10.8% | |
| Q4 2021 | +1.4% | -10.7% | +20.6% | |
| Q3 2021 | -9.8% | -13.7% | -44.4% | |
| Q2 2021 | +5.4% | +4.4% | -1.0% | |
| Q1 2021 | +13.9% | +22.8% | +59.9% | |
| Q4 2020 | -17.9% | -14.4% | -34.1% | |
| Q3 2020 | -7.4% | -5.4% | -10.7% | |
| Q2 2020 | -8.4% | -6.5% | -32.5% | |
| Q1 2020 | -8.4% | -11.8% | +21.6% | |
| Q4 2019 | -29.8% | -30.3% | -74.3% | |
| Q3 2019 | -2.1% | +17.8% | +24.4% | |
| Q2 2019 | -14.4% | -11.3% | -50.5% | |
| Q1 2019 | -11.3% | -17.0% | -28.1% | |
| Q4 2018 | +15.5% | +7.4% | -8.1% | |
| Q3 2018 | -6.0% | -5.7% | -11.9% | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro